Pfizer (PFE) quick Q4 results:

Revenues: $13,703M (+0.6%);

Innovative Health: $8,218M (+6.4%);

Essential Health: $5,484M (-7.1%).

Internal Medicine: $2,440M (+6%);

Vaccines: $1,617M (+8%);

Oncology: $1,505M (+11%);

Inflammation & Immunology: $1,104M (+8%);

Rare Disease: $603M;

Consumer Healthcare: $950M.

Legacy Established Product: $2,899M (+3%);

Sterile Injectable Pharmaceuticals: $1,404M (-8%);

Peri-LOE Product: $825M (-17%);

Biosimilars: $165M (+80%);

CentreOne: $192M (+8%).

Net Income: $12,274M;

EPS: $2.06;

Non-GAAP EPS: $0.62 (+31.9%).

2018 Guidance: Total Revenues: $53.5B – 55.5B; Non-GAAP EPS: $2.90 – 3.00.

Please Like And Share Our Content!